Immunohistochemical analysis of desmoid tumours
Open Access
- 1 November 2005
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 58 (11), 1152-1156
- https://doi.org/10.1136/jcp.2005.026278
Abstract
Background/Aims: Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens. Methods: One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0–83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors α and β, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry. Results: All samples were negative for oestrogen receptor α, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor β was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extra-abdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only. Conclusions: The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor α or c-KIT expression.Keywords
This publication has 36 references indexed in Scilit:
- Margins in extra‐abdominal desmoid tumors: A comparative analysisJournal of Surgical Oncology, 2004
- High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumorsCancer, 2004
- Antiangiogenic Treatment of Mesenteric Desmoid Tumors With Toremifene and Interferon Alfa-2b: Report of Two CasesDiseases of the Colon & Rectum, 2004
- Response of extraabdominal desmoid tumors to therapy with imatinib mesylateCancer, 2002
- Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissueThe Journal of Pathology, 2002
- Treatment of aggressive fibromatosis: A retrospective study of 72 patients followed for 1-27 yearsActa Orthopaedica, 2002
- Are Desmoid Tumors KIT Positive?The American Journal of Surgical Pathology, 2001
- Human Epidermal Growth Factor Receptor 2 as a Prognostic Indicator in Osteogenic SarcomaPublished by Ovid Technologies (Wolters Kluwer Health) ,2001
- Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT)Laboratory Investigation, 2000
- Estrogen and antiestrogen binding sites in desmoid tumorsEuropean Journal of Cancer and Clinical Oncology, 1986